U.K. medicines agency would gain advertising pre-approval rights under proposed rule.
This article was originally published in The Tan Sheet
Executive Summary
U.K. PROPOSED ADVERTISING REG WOULD ADD PRE-APPROVAL AUTHORITY to MCA ad monitoring powers, according to a draft statute issued Aug. 19 and distributed for consult Aug. 21. The proposed reg would give the U.K. Medicines Control Agency the latitude to require manufacturers of prescription, pharmacy and general sales drugs to furnish the agency with copies for review of advertisements that have been published, prepared for publication or proposed for publication, the draft rule explains. MCA additionally could require a manufacturer "to refrain from re-publishing or publishing any advertisement...without the consent of the health ministers" during the review period.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning